CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
VANCOUVER, Washington, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), today announced that updated clinical and translational data from its ongoing Phase 2 CLOVER study (ClinicalTrials.gov Identifier: NCT06699836 ) evaluating leronlimab in combination with trifluridine and tipiracil (TFD/TPI) plus bevacizumab in mCRC were presented at the ESMO Congress 2026, held October 23–27, 2026, in Madrid, Spain.